Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality

Article Page

Abstract

Background: Poor sleep may predict the increase and intensification of pain over time with increased insomnia symptoms being both a predictor and an indicator of worse pain outcomes and physical functioning status over time. However, the impact of different analgesic therapies on quality of life, functional recovery and sleep has been poorly assessed to date, whereas these evaluations may greatly help clinicians in the selection of treatment when dealing with patients with chronic pain (CP).

Methods: To explore whether tapentadol-induced pain relief may drive improved sleep quality, we carried out a pooled analysis of real-world data collected from 487 patients with CP (mean age, 68.3 years; 57.7% women) suffering from a wide range of chronic musculoskeletal pain conditions and treated with tapentadol.

Results: Following tapentadol treatment, patients experienced an 80% reduction in the frequency of very disturbed sleep as well as a 50% reduction in the predominant sleep complaint reported by patients with CP – that is, nocturnal awakenings. A significantly greater proportion of patients reported good/restful sleep at the end of the study period compared to baseline (72.4% versus 25.3%; p<0.01). This benefit was observed regardless of the clinical setting, treatment duration, posology or patient age and was associated with a higher proportion of patients reporting an improved global health status and good tolerability.

Conclusion: The reduction in pain intensity provided by tapentadol fosters sleep quality and favours a better quality of life. Therefore, our findings provide the rationale for addressing sleep quality as a relevant outcome, complementary to pain relief in CP management.

Keywords: chronic pain, functional recovery, sleep quality, tapentadol.

Citation: Vellucci R, De Rosa G, Piraccini E. Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality. Drugs in Context 2021; 10: 2020-12-9. DOI: 10.7573/dic.2020-12-9

Contributions: All authors contributed equally to this manuscript by writing the text and producing personal data and illustrations. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: R Vellucci and E Piraccini report no conflicts of interest in this work. G De Rosa is an employee of Grünenthal Italia Srl. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/03/dic.2020-12-9-COI.pdf

Acknowledgements: Statistical analysis was performed by Fabio Bravi (IBISMED Srl, Milan, Italy), and writing assistance was provided by Chiara Degirolamo, PhD. Editorial assistance was provided by Luca Giacomelli, PhD and Aashni Shah, BSc (Polistudium Srl, Milan, Italy). This assistance and fees for publications were supported by Grünenthal Italia Srl, Milan, Italy.

Funding declaration: This work was supported by Grünenthal Italia Srl.

Copyright: Copyright © 2021 Vellucci R, De Rosa G, Piraccini E. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Vellucci R, De Rosa G, Piraccini E. https://doi.org/10.7573/dic.2020-12-9. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/pain-reduction-induced-by-tapentadol-in-patients-with-musculoskeletal-chronic-pain-fosters-better-sleep-quality

Correspondence: Renato Vellucci, University of Florence, Pain and Palliative Care Clinic, University Hospital of Careggi, Florence, Italy. Email: renato.vellucci@gmail.com

Provenance: Submitted; externally peer reviewed.

Submitted: 21 December 2020; Accepted: 14 March 2021; Publication date: 19 April 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF